AIM: To explore the relationship of clinicopathological features and the distribution of neutrophils in the tumor microenvironment with the prognosis of cholangiocarcinoma. METHODS: Two hundred and fifty-four formalin-fixed and paraffin embedded tissue blocks were analyzed, including tissues from cholangiocarcinoma (n = 254), and tumor adjacent tissues (n = 238). Tissue sections were stained for CD15 using immunohistochemical staining. CD15 expression was detected to identify the distribution of neutrophils in the local tumor microenvironment. The neutrophil density of the tumor tissues and the adjacent tumor tissues was detected to reflect their inflammatory status. Clinical data and follow-up information of cholangiocarcinoma patients who underwent surgery from January 2004 to December 2010 were analyzed retrospectively. The relationship between clinicopathological features and the distribution of neutrophils with prognosis of the patients were analyzed. RESULTS: The positive expression level of CD15 was only significantly related to the TNM stage. CD15 expression was higher in tumor tissues than in adjacent tissues (73.6% vs 54.6%), with significant differences. Patients with high expression of CD15 had significantly shorter overall survival (OS) than those with low expression of CD15 (median overall survival time 39.77 mo vs 16.87 mo, P = 0.008). Patients with high CD15 expression had significantly shorter disease free survival time (DFS) than those with low expression of CD15 (median DFS 38.27 mo vs 16.83 mo, P = 0.029). COX multivariate analysis indicated that high CD15 expression in tumor tissues was an independent risk factor for predicting OS for patients with cholangiocarcinoma [P = 0.012, relative risk (RR) = 1.601], but it was not an independent risk factor for predicting DFS (P = 0.073, RR = 1.462). CONCLUSION: Patients with high CD15 expression in cancer tissues had shorter DFS and OS. High expression of CD15 is an independent risk factor for OS.
AIM: To explore the relationship of clinicopathological features and the distribution of neutrophils in the tumor microenvironment with the prognosis of cholangiocarcinoma. METHODS: Two hundred and fifty-four formalin-fixed and paraffin embedded tissue blocks were analyzed, including tissues from cholangiocarcinoma (n = 254), and tumor adjacent tissues (n = 238). Tissue sections were stained for CD15 using immunohistochemical staining. CD15 expression was detected to identify the distribution of neutrophils in the local tumor microenvironment. The neutrophil density of the tumor tissues and the adjacent tumor tissues was detected to reflect their inflammatory status. Clinical data and follow-up information of cholangiocarcinomapatients who underwent surgery from January 2004 to December 2010 were analyzed retrospectively. The relationship between clinicopathological features and the distribution of neutrophils with prognosis of the patients were analyzed. RESULTS: The positive expression level of CD15 was only significantly related to the TNM stage. CD15 expression was higher in tumor tissues than in adjacent tissues (73.6% vs 54.6%), with significant differences. Patients with high expression of CD15 had significantly shorter overall survival (OS) than those with low expression of CD15 (median overall survival time 39.77 mo vs 16.87 mo, P = 0.008). Patients with high CD15 expression had significantly shorter disease free survival time (DFS) than those with low expression of CD15 (median DFS 38.27 mo vs 16.83 mo, P = 0.029). COX multivariate analysis indicated that high CD15 expression in tumor tissues was an independent risk factor for predicting OS for patients with cholangiocarcinoma [P = 0.012, relative risk (RR) = 1.601], but it was not an independent risk factor for predicting DFS (P = 0.073, RR = 1.462). CONCLUSION:Patients with high CD15 expression in cancer tissues had shorter DFS and OS. High expression of CD15 is an independent risk factor for OS.
Authors: Yasser H Shaib; Hashem B El-Serag; Jessica A Davila; Robert Morgan; Katherine A McGlynn Journal: Gastroenterology Date: 2005-03 Impact factor: 22.682
Authors: Marisa M Queen; Randall E Ryan; Ryan G Holzer; Cynthia R Keller-Peck; Cheryl L Jorcyk Journal: Cancer Res Date: 2005-10-01 Impact factor: 12.701
Authors: Dylan Daniel; Christopher Chiu; Enrico Giraudo; Masahiro Inoue; Lee A Mizzen; N Randall Chu; Douglas Hanahan Journal: Cancer Res Date: 2005-03-01 Impact factor: 12.701
Authors: Hashem B El-Serag; Eric A Engels; Ola Landgren; Elizabeth Chiao; Louise Henderson; Harshinie C Amaratunge; Thomas P Giordano Journal: Hepatology Date: 2009-01 Impact factor: 17.425
Authors: Marian M H Claessen; Frank P Vleggaar; Kristien M A J Tytgat; Peter D Siersema; Henk R van Buuren Journal: J Hepatol Date: 2008-10-14 Impact factor: 25.083
Authors: Tae Y Lee; Sang S Lee; Seok W Jung; Seong H Jeon; Sung-Cheol Yun; Hyoung-Chul Oh; Seunghyun Kwon; Sung K Lee; Dong W Seo; Myung-Hwan Kim; Dong J Suh Journal: Am J Gastroenterol Date: 2008-06-28 Impact factor: 10.864
Authors: Vinit Kumar; Laxminarasimha Donthireddy; Douglas Marvel; Thomas Condamine; Fang Wang; Sergio Lavilla-Alonso; Ayumi Hashimoto; Prashanthi Vonteddu; Reeti Behera; Marlee A Goins; Charles Mulligan; Brian Nam; Neil Hockstein; Fred Denstman; Shanti Shakamuri; David W Speicher; Ashani T Weeraratna; Timothy Chao; Robert H Vonderheide; Lucia R Languino; Peter Ordentlich; Qin Liu; Xiaowei Xu; Albert Lo; Ellen Puré; Chunsheng Zhang; Andrey Loboda; Manuel A Sepulveda; Linda A Snyder; Dmitry I Gabrilovich Journal: Cancer Cell Date: 2017-11-13 Impact factor: 31.743
Authors: Vittorio Branchi; Benedict Jürgensen; Laura Esser; Maria Gonzalez-Carmona; Tobias J Weismüller; Christian P Strassburg; Jonas Henn; Alexander Semaan; Philipp Lingohr; Steffen Manekeller; Glen Kristiansen; Jörg C Kalff; Marieta I Toma; Hanno Matthaei Journal: J Pers Med Date: 2021-03-23